Somewhat Late To The HCV Race, Novartis Licenses NS5A Inhibitor From Enanta
This article was originally published in The Pink Sheet Daily
The Phase I-ready compound joins alisporivir, a cyclophilin inhibitor licensed from Debiopharm in 2010, in Novartis’ rather slight portfolio of HCV candidates.
You may also be interested in...
Abandoned deals were the order of the week as the Salix/Cosmo breakup followed Novartis’ exit from hepatitis C drug development and a partnership in that space with Enanta. J&J, however, increased its bet on HCV by acquiring Alios, one of several noteworthy buyouts occurring during the week.
A pair of biotech IPOs priced on March 20 with mixed results. Hepatitis C developer Enanta got a warm reception from investors looking to tap into what has been a lucrative sector. But antibiotics company Tetraphase priced below its range and traded flat.
Novartis and Idenix have all but ended the co-development and commercialization agreement that was established in 2003 and gave Novartis a controlling option in the company.